The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab-Reference-Cited by-同舟云学术

The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab

Published:2016-05-16 Issue:1 Volume:27 Page:42-49
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:Modern Rheumatology

Author:

Kaneshiro Shoichi¹²³,Ebina Kosuke²,Hirao Makoto²,Tsuboi Hideki³,Nishikawa Masataka¹,Nampei Akihide⁴,Nagayama Yoshio³,Takahi Koichiro⁵,Noguchi Takaaki²,Owaki Hajime¹,Hashimoto Jun⁶,Yoshikawa Hideki²

Affiliation:

1. Department of Orthopaedic Surgery, Japan Community Healthcare Organization, Osaka Hospital, Osaka, Japan,

2. Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan,

3. Department of Orthopaedic Surgery, Osaka Rosai Hospital, Osaka, Japan,

4. Department of Orthopaedic Surgery, National Hospital Organization Osaka Minami Medical Center, Osaka, Japan,

5. Department of Orthopaedic Surgery, Toneyama National Hospital, Osaka, Japan, and

6. Department of Rheumatology, National Hospital Organization Osaka Minami Medical Center, Osaka, Japan

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14397595.2016.1181315

Reference34 articles.

1. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

2. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

3. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

4. Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab

5. IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Add-on effectiveness of methotrexate or iguratimod in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors: The ANSWER cohort study;Modern Rheumatology;2022-08-13

2. Current status and prospects of IL-6–targeting therapy;Expert Review of Clinical Pharmacology;2022-05-04

3. Effectiveness of tacrolimus concomitant with biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis;Modern Rheumatology;2022-03-15

4. Safety of Tacrolimus in Autoimmune Disease: Results From Post-marketing Surveillance in South Korea;Journal of Rheumatic Diseases;2021-10-01

5. Concomitant Treatment with Etanercept and Tacrolimus Synergistically Attenuates Arthritis Progression via Inhibition of Matrix Metalloproteinase-3 Production and Osteoclastogenesis in Human TNF-α Transgenic Mice;Mediators of Inflammation;2019-12-17